Taimur T. Shah
Imperial College London
CancerInternal medicineRadiologyUrologySurgeryMagnetic resonance imagingUltrasoundOncologyBiopsyProstateHigh-intensity focused ultrasoundBrachytherapyDiseaseProstatectomyCryotherapyProstate cancerSalvage therapyProstate biopsyFocal therapyIn patientRadiation therapyMedicine
106Publications
15H-index
514Citations
Publications 108
Newest
#9Alistair Grey (Imperial College Healthcare)H-Index: 5
Abstract Background Multiparametric magnetic resonance imaging (mpMRI) is now recommended prebiopsy in numerous healthcare regions based on the findings of high-quality studies from expert centres. Concern remains about reproducibility of mpMRI to rule out clinically significant prostate cancer (csPCa) in real-world settings. Objective To assess the diagnostic performance of mpMRI for csPCa in a real-world setting. Design, setting, and participants A multicentre, retrospective cohort study, incl...
Source
#1Emily Day (ICL: Imperial College London)H-Index: 2
#2A Toby Prevost ('KCL': King's College London)H-Index: 43
Last. Vincent Khoo (The Royal Marsden NHS Foundation Trust)H-Index: 64
view all 0 authors...
BACKGROUND Randomised controlled trials (RCTs) for surgical interventions have often proven difficult with calls for innovative approaches. The Imperial Prostate (IP4) Comparative Health Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS) study aims to deliver level 1 evidence on outcomes following focal therapy which involves treating just the tumour rather than whole-gland surgery or radiotherapy. Our aim is to test the feasibility of two parallel RCTs within an overarching str...
Source
#1Taimur T. ShahH-Index: 15
#2Abi KanthabalanH-Index: 11
Last. Alex FreemanH-Index: 26
view all 25 authors...
Source
#1Alistair GreyH-Index: 5
Last. Taimur T. ShahH-Index: 15
view all 24 authors...
Source
#1Deepika ReddyH-Index: 3
#2Max PetersH-Index: 14
Last. Tim DudderidgeH-Index: 20
view all 25 authors...
Source
#1Deepika ReddyH-Index: 3
#2Max PetersH-Index: 14
Last. Philipp M. HuberH-Index: 3
view all 25 authors...
Source
#1Alistair Grey (UCL: University College London)H-Index: 5
#2R. Scott (UCL: University College London)H-Index: 6
Last. Diane Campbell (St Bartholomew's Hospital)
view all 20 authors...
Source
#1Taimur T. Shah (ICL: Imperial College London)H-Index: 15
#2Abi Kanthabalan (UCL: University College London)H-Index: 11
Last. Ashok NikapotaH-Index: 1
view all 20 authors...
Source
#1Arnas Rakauskas (ICL: Imperial College London)
#2Taimur T. Shah (ICL: Imperial College London)H-Index: 15
Last. Hashim U. Ahmed (ICL: Imperial College London)H-Index: 64
view all 11 authors...
Abstract Objectives Focal salvage HIFU is a feasible therapeutic option in some men who have recurrence after primary radiotherapy for prostate cancer. We aimed to determine if multi-parametric quantitative parameters, in addition to clinical factors, might have a role in independently predicting focal salvage HIFU outcomes. Methods A retrospective registry analysis included 150 consecutive men who underwent focal salvage HIFU (Sonablate500) (2006-2015); 89 had mpMRI available. Metastatic diseas...
Source
#1S. Khadhouri (Aberd.: University of Aberdeen)H-Index: 2
#2Kevin M Gallagher (Western General Hospital)H-Index: 6
Last. Veeru Kasivisvanathan (UCL: University College London)H-Index: 18
view all 38 authors...
OBJECTIVE To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer (UTUC) and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND METHODS This was an international multicentre prospective observational study. We included patients aged 16 and over, referred to secondary care with suspected urinary tract cancer. Patients with a known or prev...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.